, Tracking Stock Market Picks
Enter Symbol:

up 5.79 %

PHARMATHENE INC (PIP) rated Buy with price target $6 by Aegis Capital

Posted on: Wednesday,  Mar 6, 2013  9:25 AM ET by Aegis Capital

Aegis Capital rated Buy PHARMATHENE INC (AMEX: PIP) on 03/06/2013, when the stock price was $1.38. Since
then, PHARMATHENE INC has gained 5.80% as of 08/27/2015's recent price of $1.46.
If you would have followed this Aegis Capital's recommendation on PIP, you would have gained 5.79% of your investment in 904 days.

PharmAthene, Inc. (PharmAthene), formerly Healthcare Acquisition Corp., is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. The Company has five product candidates in various stages of development, which include SparVax, Valortim, Protexia, RypVax and a third generation recombinant protective antigen (rPA) anthrax vaccine. SparVax is a second generation rPA anthrax vaccine. Valortim is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. Protexia mimics a natural bioscavenger for the treatment or prevention of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. RypVax is a recombinant dual antigen vaccine for pneumonic and bubonic plague. On April 2, 2008, the Company acquired Avecia?s biodefense vaccines business from Avecia Biologics Limited and certain of its affiliates.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2013 9:25 AM Buy
1.38 6.00
as of 12/13/2013
1 Week down  -1.47 %
1 Month up  2.04 %
3 Months down  -5.66 %
1 YTD up  44.92 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy